Showing results (31-40 of 49) with videos related to
Sort By:
Pageof 5
Cancer Chemotherapy and Pharmacology|January 1, 1992
Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbitB J Cusack, S P Young, V L Loseke, et al.Cancer Chemotherapy and Pharmacology|March 24, 2006
Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolismB J Cusack, H Gambliel, B Musser, et al.Biochemical Pharmacology|February 15, 1990
Taurine deficiency and doxorubicin: interaction with the cardiac sarcolemmal calcium pumpH Harada, B J Cusack, R D Olson, et al.Toxicology and Applied Pharmacology|February 1, 1993
Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol?B J Cusack, P S Mushlin, L D Voulelis, et al.The Journal of Pharmacology and Experimental Therapeutics|May 1, 1988
Aging and drug interactions. II. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy menJ J Crowley, B J Cusack, S G Jue, et al.Cancer Chemotherapy and Pharmacology|January 1, 1988
Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbitB J Cusack, D A Tesnohlidek, V L Loseke, et al.The Journal of Clinical Investigation|April 1, 1993
Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit modelD A Dodd, J B Atkinson, R D Olson, et al.Journal of Clinical Pharmacology|April 10, 1999
Effect of troglitazone on the pharmacokinetics of an oral contraceptive agentC M Loi, R Stern, J R Koup, et al.Proceedings of the National Academy of Sciences of the United States of America|May 1, 1988
Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinolR D Olson, P S Mushlin, D E Brenner, et al.Journal of Clinical Pharmacology|March 20, 1998
Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolitesC M Loi, C W Alvey, E J Randinitis, et al.Pageof 5